The future of interleukin-2: Enhancing therapeutic anticancer vaccines

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Overwijk, Willem W ^a   Theoret, Marc R ^b   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Adjuvant; Cancer vaccines; Gp 100; Interleukin 2; Melanoma; T lymphocytes

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TUMOR ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; DNA; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 7; MELANOMA ANTIGEN;

APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL PROLIFERATION; HUMAN; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; REVIEW; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS;

EID: 0033846635     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy fot patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
2. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
3. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
4. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-484; discussion 484-485.
5. Mule JJ, Yang JC, Lafreniere RL et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987;139:285-294.
6. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
7. Restifo NP, Rosenberg SA Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999;11:50-57.
8. Bronte V, Tsung K, Rao JB et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in die treatment of established pulmonary metastases. J Immunol 1995;154:5282-5292.
9. Rao JB, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-3365.
10. Sun S, Kishimoto H, Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynudeotides to augment T cell responses to specific antigen. J Exp Med 1998;187:1145-1150.
11. Irvine KR, Rao JB, Rosenberg SA et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-245.
12. Chamberlain RS, Carroll MW, Bronte V et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996;56:2832-2836.
13. Gurunathan S, Irvine KR, Wu CY et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998;161:4563-4571.
14. Fields PE, Finch RJ, Gray GS et al. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol 1998;161:5268-5275.
15. Carroll MW, Overwijk WW, Chamberlain RS et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997;15:387-394.
16. Chen PW, Wang M, Bronte V et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996;156:224-231.
17. Restifo NP, Surman DR, Zheng H et al. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology 1998;249:89-97.
18. Ying H, Zaks TZ, Wang RF et al. Cancer therapy using a self-replicating RNA vaccine. Nature Med 1999;5:823-827.
19. Overwijk WW, Tsung A, Irvine KR et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-286.
20. Hemler ME, Brenner MB, McLean JM et al. Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells. Proc Natl Acad Sci USA 1984;81: 2172-2175.
21. Alexander RB, Rosenberg SA. Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. J Immunother 1991;10:389-397.
22. Wong RA, Alexander RB, Puri RK et al. In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunorher 1991;10:120-130.
23. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321.
24. Dudley ME, Nishimura MI, Holt AK et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999;22:288-298.
25. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4:321-327.
26. Bronte V, Wang M, Overwijk WW et al. Apoptoric death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998;161:5313-5320.
27. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999;163:1690-1695.
28. Alderson MR, Lynch DH. Receptors and ligands that mediate activation-induced death of T cells. Springer Semin Immunopathol 1998;19:289-300.
29. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-988.
30. Zaks TZ, Chappell DB, Rosenberg SA et al. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 1999;162:3273-3279.
31. Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-77.
32. Gribben JG, Freeman GJ, Boussiotis VA et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995;92:811-815.
33. Zhou T, Edwards CK 3rd, Yang P et al. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661-2665.
34. Kundig TM, Schorle H, Bachmann MF et al. Immune responses in interleukin-2-deficient mice. Science 1993;262:1059-1061.
35. Kneitz B, Herrmann T, Yonehara S et al. Normal clonal expansion but impaired Fas-mediated cell deadi and anergy induction in interleukin-2-deficient mice. Eur J Immunol 1995;25: 2572-2577.
36. Tucek-Szabo CL, Andjelic S, Lacy E et al. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor. J Immunol 1996;156:192-200.